Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	15^th September 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,307,466 (1.882%)		-
(2) Derivatives (other than options)	-		496,000 (0.217%)
(3) Options and agreements to purchase/sell	822,900 (0.359%)		1,067,700 (0.466%)
Total	5,130,366 (2.241%)		1,563,700 (0.683%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	40	115.35
Purchase	113	115.31
Sale	40	115.31
Purchase	22	115.26
Purchase	11	115.28
Purchase	54	115.29
Sale	111	115.35
Sale	41	115.37
Sale	2	115.33
Sale	2,108	115.31
Sale	16	115.36
Purchase	18	115.32
Sale	86	115.32
Sale	41	115.34
Purchase	119	115.26
Purchase	9	115.28
Purchase	36	115.30
Purchase	18	115.25
Purchase	130	115.23
Sale	1,829	115.35
Purchase	155	115.31
Purchase	563	115.26
Purchase	232	115.28
Purchase	88	115.21
Purchase	311	115.29
Purchase	480	115.30
Sale	2	115.35
Sale	1	115.33
Sale	1	115.32
Sale	3,143	115.15
Sale	8,307	115.17
Sale	8,550	115.16
Purchase	1	115.27

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price (USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)
Call Option	300	100.00
Call Option	135,000	110.00
Call Option	18,000	105.00

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	18^th September 2023
Contact name	Stephen Glasper
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	100,300	90.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Written	284,900	60.00	American	12/15/2023
IE00BQPVQZ61	Put Option	Written	100,000	65.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	55,000	70.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Written	41,500	45.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	250,000	85.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	152,500	110.00	American	11/17/2023
IE00BQPVQZ61	Call Option	Purchased	4,500	110.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	100,000	100.00	American	12/15/2023
IE00BQPVQZ61	Call Option	Written	100,000	110.00	American	12/15/2023
IE00BQPVQZ61	Call Option	Written	3,400	100.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	2,800	100.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	150,000	85.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	2,600	90.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	40,900	100.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	41,500	65.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Written	600	100.00	American	10/20/2023
IE00BQPVQZ61	Put Option	Purchased	100,000	70.00	American	11/17/2023
IE00BQPVQZ61	Call Option	Purchased	200	115.00	American	12/15/2023
IE00BQPVQZ61	Put Option	Written	100,000	60.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	35,200	110.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	54,800	115.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	400	105.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Written	400	105.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	27,000	95.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	300	115.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	7,800	115.00	American	11/17/2023
IE00BQPVQZ61	Put Option	Purchased	4,800	115.00	American	11/17/2025
IE00BQPVQZ61	Put Option	Purchased	2,600	115.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	115,000	115.00	American	10/20/2023
IE00BQPVQZ61	Put Option	Purchased	11,300	115.00	American	12/15/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1162130

Time of Receipt (offset from UTC): 20230918T144556+0100